2-Fluoro-4-nitrobenzoic acid CAS:403-24-7

2-Fluoro-4-nitrobenzoic acid

Chemical Name:2-Fluoro-4-nitrobenzoic acid
CAS.NO:403-24-7
Synonyms:2-Fluoro-4-nitrobenzoic acid
Molecular Formula:C7H4FNO4
Molecular Weight:185.10900
 
Physical and Chemical Properties:
Density:1.568;
Melting point:170oC;
Boiling point:352.5oC;
Flash point:167oC;
 
Specification:
Appearance:White to pale yellow or light brown powder
Purity(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis



We are professional 2-Fluoro-4-nitrobenzoic acid manufacturer and 2-Fluoro-4-nitrobenzoic acid supplier in China, We offer quality 2-Fluoro-4-nitrobenzoic acid you can fully trust, also we have India factory and producer of 2-Fluoro-4-nitrobenzoic acid,Pls send inquiry of 2-Fluoro-4-nitrobenzoic acid CAS:403-24-7 to info@nbinno.com if you have any interests, thank you!


Related News: GlaxoSmithKline’s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.5-Bromo-2-fluoro-4-methylbenzaldehyde CAS:497224-12-1 Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”Trifluoromethanesulfonicanhydride Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).2,3,4-Trifluorobromobenzene CAS:176317-02-5 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank.